The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline.

被引：0
|
作者：
Preskorn, SH
Shah, R
Silkey, B
Neff, M
Golbeck, A
Choi, J
机构：
[1] Vet Affairs Med Ctr, Wichita, KS USA
[2] Inst Psychiat Res, Wichita, KS USA
[3] Vet Integrated Serv Network, Bay Pines, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.266
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P71 / P71
页数：1
相关论文
共 50 条
  • [1] The potential for clinically significant drug-drug interactions in patients receiving CYP 2136 model substrate/drugs and fluoxetine/paroxetine or sertraline
    Preskorn, S
    Shah, R
    Silkey, B
    Neff, M
    Golbeck, A
    Choi, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S228 - S228
  • [2] The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetineiparoxetine or sertraline
    Preskorn, SH
    Shah, R
    Silkey, B
    Neff, M
    Golbeck, A
    Choi, J
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S285 - S285
  • [3] Relationship of venlafaxine, fluoxetine, sertraline, and paroxetine plasma concentration with CYP 2D6 inhibition
    Alfaro, C
    Ereshefsky, L
    Lam, YWF
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 488 - 488
  • [4] The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
    Bahar, Muh. Akbar
    Kamp, Jasper
    Borgsteede, Sander D.
    Hak, Eelko
    Wilffert, Bob
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2704 - 2715
  • [5] Predictors of potential clinically significant drug-drug interactions in patients with heart failure.
    Kovacevic, Milena
    Kovacevic, Sandra Vezmar
    Miljkovic, Branislava
    Radovanovic, Slavica
    PHARMACOTHERAPY, 2016, 36 (07): : E87 - E87
  • [6] The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly
    Bahar, Muh Akbar
    Hak, Eelko
    Bos, Jens H. J.
    Borgsteede, Sander D.
    Wilffert, Bob
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (07) : 752 - 765
  • [7] The impact of CYP2D6 mediated drug-drug interaction in elderly: Co-prescription of metoprolol and paroxetine/ fluoxetine
    Bahar, Muh Akbar
    Wang, Yuanyuan
    Bos, Jens H. J.
    Wilffert, Bob
    Hak, Eelko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 291 - 291
  • [8] In Silico Model for Predicting CYP2D6-Mediated Drug-Drug Interactions
    Lozano, Roberto
    Frutos, Alberto
    Martinez, Alejandro
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2021, 16 (02) : 124 - 127
  • [9] CYP2D6 "humanized" mice: A model for in vivo pharmacokinetics and drug-drug interactions
    Corchero, J
    Pimprale, S
    Krausz, K
    Gelboin, HV
    Gonzalez, J
    FASEB JOURNAL, 2000, 14 (08): : A1437 - A1437
  • [10] The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness
    Monte, Andrew A.
    Heard, Kennon J.
    Campbell, Jenny
    Hamamura, D.
    Weinshilboum, Richard M.
    Vasiliou, Vasilis
    ACADEMIC EMERGENCY MEDICINE, 2014, 21 (08) : 879 - 885
12345